 power forward power curv genco mtm weekli commentari
medic suppli devic chart week med-tech name over/under-own top healthcar
upcom teleconfer pre- call kol upcom event hear thought
abstract theyll look confer
biotechnolog pubm pregam frizz-if aav
medic suppli devic aha takeaway ischemia impact readthrough earli tavr bad news
page analyst certif import disclosur
see record price super bowl spot anti-trust probe expand android work bring programmat
podcast
 protector trial fail rti downgrad neutral
publish novemb
messag today announc inhibitor phase protector trial elderli respiratori tract infect rti
southern hemispher fail demonstr improv vs pbo patient treat odd experienc rti
vs pbo odd ratio due data second protector ii trial cancel though continu
pursu parkinson goal induc autophagi brain clear aggreg data given today news
downgrad neutral buy remov pt previous estim cash expect share trade
rang
aha moment lacroix reiter sell
publish novemb
messag revis expect ahead result expect earli decemb date unknown
expect year look broadli similar previous model incorpor estim impact upcom aha brand launch
march expect take shelf space share lacroix continu think lacroix stabil least next year given
increas competit lack meaning innov gener buzz lower ep estim
 reduc price target due lower estim
page analyst certif import disclosur
address long-term short argument updat
model pt
publish novemb
messag near-term bear argument follow center around erod kpi includ increas custom
acquisit cost increas invoic cost lower sequenti long-term valuat pet silenc revers trend
said stock still almost short interest long-term bear argument seem remain address see strongest
bear argument take bullish side even stock sinc week low oct vs
think upsid potenti remain pt
publish novemb
messag updat estim follow recent report quarter reiter pt
price target
publish novemb
messag macro trend continu weigh top-line growth tcom kept lid spend highlight revenu met modest guidanc
continu slow transport revenu low singl digit oper incom top guidanc growth acceler
on-going focu effici particularli guidanc point revenu deceler opex flat sequenti
page analyst certif import disclosur
margin last year maintain neutral rate estim said tcom histor multipl premium larg gone
project growth estim still excess
gd strong print custom demand acceler
publish novemb
messag gd post strong result management highlight trend acceler demand among top custom notabl deal size
gradual increas gd saw deal well deal new custom look management
increasingli confid achiev sqm new book better see on-going margin improv remain suffici fund
base current outlook maintain buy pt
 buy expect improv uninspir print guidestay
buy brand algo valuat spread dg
publish novemb
messag like deliv sequentially-improv oper momentum segment larg abat gross margin pressur
said expect mute reaction print first share risen past three month vs partial recognit
improv second absolut bottom-lin result remain uninspir secular algowith total ebitda rise base
estim third segment face stiffen comp compar amid uncertainti shorter holiday sell season stay buy rate believ
share still rel under-valu see exhibit
readi hit ebitda target reiter buy
publish novemb
messag prior call manag adj ebitda consensu guidanc manag walk us
concern unfound reiter confid guidanc walk concern quarter manag
feel comfort one quarter servic slowdown temporari market growth would off-set e-tailer/retail loss overal
doubl digit growth seen year continu next year manag confid cfo bought almost full year comp
worth stock increas ebitda number reflect manag confid busi
page analyst certif import disclosur
buy meet manag confirm pipelin
remain track burn
publish novemb
messag host lunch meet chri bowden cfo head corpor develop andrew hirsch svp
commerci global market darrin mile vice-president extern commun investor relat kendra adam convers
manag re-affirmed confid tibsovo growth potenti current approv indic confirm poc data mitapivat
thalassemia present confirm pilot trial remain on-going state plan keep
cash burn level
forward power curv genco mtm weekli commentari
publish novemb
weekli power capac market polici highlight guggenheim takeaway page report
note two-week comparison
messag week week nation atc spark spread higher larg gain western market nyiso off-set flat-
to-slightly-low spark eastern market ercot region spark higher pac northwest desert southwest
ercot lost ercot spark led lower decreas off-peak spread decreas peak spread nyiso spark
higher overal led increas off-peak spark peak spark gain atc power price higher
averag increas western rto eastern rto modestli lower delta
eastern rto power price ercot rose natur ga price end higher henri hub price increas ga held
back decreas ny new england pjm respect region saw gain rang
texa price rose ipp genco mark recov vs end june mark week-over-week
novo rybelsu trx come strong color
capit market day
publish novemb
page analyst certif import disclosur
messag earli rybelsu oral semaglutid type diabet rx continu strong week post launch drive share buy-
rate novo b-cse earli trx data show rybelsu well ahead recent launch either trulic ozemp line jardianc
today lead impress initi launch invokana assum uptak primarili driven particip
novo co-pay program continu posit novo futur growth prospect driven semaglutid franchis rybelsu ozemp
mg weekli ozemp mg weekli ozemp mg weekli obes remain buy rate novo
chart week med-tech name over/under-own top healthcar fund
publish novemb
messag one question frequent get investor whether certain stock sector over-own crowd long
file due today week cotw analyz recent hold top healthcar fund see name least
popular across med-tech portfolio overal analysi show see rise ownership throughout group hold level trend lower
sit modestli histor averag databas go back
publish novemb
messag week featur result wix analyst day initi read wix result focu in-lin revenu ep
perform later saw neg reaction investor due guidanc impli sharp drop premium subscrib y/i
gross margin contract due payment growth day report wix finish flat investor day
featur entir c-suit includ number key hire made last year focu event product roadmap enhanc
ai path billion revenu grow up-market custom pay recent quarter
decemb ndr new york
decemb ndr boston
pubm pregam frizz-if aav
publish novemb
messag peak winter nyc week let take mental vacay imagin hot humid summer day get readi
morn think wow hair look great time get work someth gone horribl wrong hairdo
okay mayb curlyhairproblem real turn similar thing happen protein viral vector
refer frizz-if hair kind like post-transl modif ptm protein way hair look
arriv left apart protein also undergo unintend chang manufactur biolog
page analyst certif import disclosur
manufactur ptm highli character control impact safeti efficaci aav though
great understand ptm happen control least
 closer look iqvia rivalri
publish novemb
messag iqvia oce platform gain custom traction elev investor concern around competit landscap
commerci cloud call enterpris oce win follow updat strategi understand factor
contribut recent uptick custom interest adopt also connect former two enterpris pharmaceut compani
understand custom prefer recent lt target compound-annual-growth-rate cc investor expect could see greater
scrutini competit intensifi said remain posit buy rate anchor primarili growth potenti vault
buy lay risk reward narcan ip decis ahead
investor day
publish novemb
messag reach revenu year earli expect focu investor day week center new growth plan
particularli on-going gener litig narcan ip front see attract risk/reward ip decis scenario analysi
board overse ipr suggest formul patent may hold relat guidanc think may provid
compon growth organ vs inorgan also remain conserv narcan given histori product uncertainti relat
time brand competit addit state adopt co-rx legisl
aha takeaway ischemia impact readthrough earli tavr bad news impella
publish novemb
messag attend aha scientif session weekend featur much-anticip result ischemia trial well
sever session interest across tavr hemodynam support market overal believ ischemia like lead modestli
reduc stent volum physician confid defer intervent asymptomat patient stabl cad despit presenc ischemia
howev expect impact manag popul repres highli select subgroup elsewher posit data savr
asymptomat patient mix implic earli tavr trial marvel result pave way mdt micra receiv
expand fda label neg comparison impella vs iabp could cloud clinic rational technolog
page analyst certif import disclosur
spot anti-trust probe expand android work bring programmat podcast
publish novemb
viab morri see strong turnaround paramount am posit compani futur growth maintain buy rate merger cb remain
track close earli decemb
publish novemb
guggenheim host client util event includ ndr
schedul scroll
houston problem puct environ deterior un-invest nt downgrad neutral see note
njr/sji/so penneast announc pursu scotu appeal circuit appeal decis regard emin domain
dominion file rebutt testimoni request renew energi tariff design rider
river project announc invest two solar plu storag project
pjm imm releas quarterli state market report pjm
doe deputi secretari brouillett comment baseload confirm hear
page analyst certif import disclosur
inc
page analyst certif import disclosur
primari analyst jake fuller
page analyst certif import disclosur
primari analyst glen santangelo
page analyst certif import disclosur
explor product
page analyst certif import disclosur
life scienc tool omic
primari analyst david westenberg cfa
coverag seamu fernandez
page analyst certif import disclosur
